CV Therapeutics Inc Watch

from 10-Q 73 pages License, Development and Supply Agreement Between Menarini International Operations Luxembourg SA and CV Therapeutics, Inc

from 10-Q 6 pages Intellectual Property Security Agreement

from 10-Q 68 pages Asset Sale and Purchase Agreement

from 10-K 22 pages Amended and Restated Employment Agreement

from 10-Q 15 pages Amended and Restated Executive Severance Benefits Agreement

from 10-Q 15 pages Amended and Restated Executive Severance Benefits Agreement

from 10-Q 15 pages Amended and Restated Executive Severance Benefits Agreement

from 10-Q 15 pages Amended and Restated Executive Severance Benefits Agreement

from 10-Q 17 pages CV Therapeutics, Inc. Change in Control Plan With Respect to Options and Severance

from 10-Q 16 pages Amended and Restated CV Therapeutics, Inc. Long-Term Incentive Plan

from 10-Q 14 pages Amended and Restated Executive Severance Benefits Agreement

from 8-K ~10 pages This Instrument of Resignation, Appointment and Acceptance (This “Instrument”), Dated as of September 18, 2007 (“Effective Date”), Is by and Among CV Therapeutics, Inc., a Corporation Duly Organized and Existing Under the Laws of the State of Delaware (The “Company”), US Bank National Association, a National Banking Association Duly Organized and Existing Under the Laws of the United States (The “Successor Trustee” and “Successor Escrow Agent”), and Wells Fargo Bank, National Association, a National Banking Association Duly Organized and Existing Under the Laws of the United States (The “Resigning Trustee” and “Resigning Escrow Agent”). Capitalized Terms Not Otherwise Defined Herein Shall Have the Same Meaning Ascribed to Such Terms in the Indentures (As Defined Below) as Applicable

from 10-Q 2 pages Convertible Promissory Note Amendment No. 1 1

from 10-Q 6 pages CV Therapeutics, Inc. Requests That the Marked Portions of the Exhibit Be Granted Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. Amendment No. 1 to Collaboration and License Agreement

from 10-Q 14 pages CV Therapeutics, Inc. 2004 Employment Commencement Incentive Plan Adopted by the Board of Directors December 14, 2004 Amended and Restated by the Board of Directors May 31, 2007

from 10-Q 2 pages CV Therapeutics, Inc. Requests That the Marked Portions of the Exhibit Be Granted Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. License Agreement Amendment No. 4

from 10-Q 74 pages CV Therapeutics, Inc. Requests That the Marked Portions of the Exhibit Be Granted Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. Collaboration and License Agreement by and Between CV Therapeutics, Inc. and Ptc Therapeutics, Inc. June 7, 2006

from 10-Q 4 pages Second Amendment to Collaboration and License Agreement

from 8-K 44 pages Common Stock Purchase Agreement Dated April 18, 2006 by and Between CV Therapeutics, Inc. and Azimuth Opportunity Ltd

from 10-K 2 pages Amendment No. 1 Co-Promotion Agreement CV Therapeutics, Inc. and Solvay Pharmaceuticals, Inc